Treatment of sulphasalazine-induced agranulocytosis with granulocyte macrophage-colony stimulating factor
| Autor: | H Dorrance, M K Cook, J B Rainey, P Roddie |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Granulocyte Neutropenia Gastroenterology Gastrointestinal Agents Sulfasalazine Internal medicine medicine Humans Pharmacology (medical) Chemotherapy Leukopenia Hepatology business.industry Granulocyte-Macrophage Colony-Stimulating Factor medicine.disease Ulcerative colitis medicine.anatomical_structure Granulocyte macrophage colony-stimulating factor Immunology Colitis Ulcerative medicine.symptom Complication business medicine.drug Agranulocytosis |
| Zdroj: | Alimentary pharmacologytherapeutics. 9(6) |
| ISSN: | 0269-2813 |
| Popis: | Sulphasalazine-induced agranulocytosis is a rare but potentially life threatening complication. A variable mortality rate has been reported, from 6% to 20%, and is related to the duration of neutropenia. Previous case reports have shown that the use of granulocyte macrophage-colony stimulating factor (GM-CSF) in treating drug-induced agranulocytosis may shorten the period of neutropenia and hence lead to improved survival. It may also be a less costly treatment option that supportive care alone due to reduction of hospital stay as a consequence of a shortened duration of neutropenia. We report a case in which sulphasalazine had been used in the treatment of ulcerative colitis and the subsequent agranulocytosis was treated successfully with GM-CSF, something which has hitherto been unreported. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text